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Summary From November 1977 to July 1983, 82 children with T leukaemia/lymphoma entered a randomised trial of combination chemotherapy and radiotherapy. Twenty-five were designated T lymphoma and 57 T leukaemia, 28 having > 100 x 1091 1 blasts in peripheral blood at diagnosis. Twenty-seven patients with mediastinal primaries who were treated on the companion non-Hodgkin lymphoma (NHL) trial were comparable in all respects to the T lymphoma patients and the results of treatment were therefore combined and analysed together. Overall 4-year survival (48-53%) and failure-free survival (FFS) (37-40%) were similar in all groups except the 28 with T leukaemia and WCC>100 x 10 1-1 (20% and 13%). There was a significant advantage in FFS for patients randomised to receive low dose mediastinal radiation, and this was most marked in patients with T lymphoma (66% vs 18%, P=0.006).
One of the most important advances in our
understanding of the leukaemias and lymphomas of
childhood has been the recognition that they are
biologically a heterogeneous group of disorders.
Ten to 20% of children with a morphological
diagnosis of acute lymphoblastic leukaemia (ALL)
have lymphoblasts whose surface receptors indicate
a T cell lineage, and these patients have an inferior
prognosis when compared to patients with common
ALL (Chessells et al., 1977). About one-third of
children with NHL present with a mediastinal mass
and the lymphoblasts from these lymphomas
likewise indicate a T cell lineage. The natural
history of T cell lymphoma is for almost universal
progression to involvement of the bone marrow
and CNS (Watanabe et al., 1973) and it is highly
likely that T cell lymphoma and T cell leukaemia
are, in fact, different stages in the evolution of one
disorder. There are minor differences in the
phenotype of lymphoblasts in T lymphoma and T
leukaemia (Roper et al., 1983) but nothing to
indicate that they should not be regarded as
essentially the same disease.
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Treatment with the combination of radiation
therapy to sites of bulk disease and an intensive
multi-agent chemotherapy programme initially
designed for the treatment of childhood ALL, but
with the addition of early cyclophosphamide (the
LSA2-L2 protocol), resulted in a dramatic
improvement in the prognosis for childhood non-
Hodgkin lymphoma (NHL), particularly for those
patients who presented with a mediastinal mass
(Wollner et al., 1976). In 1977, therefore, six of the
centres within the UK Children's Cancer Study Group decided to submit all patients with either T
lymphoma or T leukaemia to an intensified variant
of our NHL protocol (Mott et al., 1984), the design of which is in some respects similar to the LSA2-L2
regimen.
Patients and methods
The treatmentprotocol
The NHL protocol, previously described (Mott et
al.; 1984 was modified as follows (Figure 1):
1. Induction courses of CHOP were strengthened
by the addition of a second injection of
vincristine, 1.5 mgm2 on day 8, and the
continuation of prednisone for 10 instead of 5
days.
2. Treatment courses were given as soon as
marrow recovery permitted (usually 12-15 days) rather than at specified 3 week intervals.
3. The two 4-day courses of cytosine arabinoside
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Figure 1 Treatment Schema.
and thioguanine were condensed to form a single
10-day course during which asparaginase was
added (CA 100mgm-2, 12 hourly x 20, TG
75 mgm-2 daily x 10, IV Asparaginase 10,000
units m-2 alternate days x 5).
4. The three courses of intermediate dose
methotrexate given as consolidation therapy
were at one week rather than 2 week intervals.
5. All patients received cranial radiation, 17.6 Gy in
8 fractions given over 2 weeks. In addition,
patients were randomly assigned to receive or
not to receive 15 Gy to the mediastinum
concurrently, irrespective of whether there was a
mediastinal mass present at diagnosis.
6. Systemic treatment during radiation therapy
consisted of a 2-week course of prednisone,
40mgm 2 per day and weekly vincristine.
As in the NHL regimen, all patients received a
total of 7 doses of intrathecal methotrexate,
10mgm2 (maximum 12mg) during the induction
and consolidation phases.
The maintenance treatment was identical to that
for patients with mediastinal primaries on the NHL
trial, with oral rather than i.v. methotrexate because
of previous cranial radiation, and was continued to
complete 2 years of chemotherapy.
Patient entry
From November 1977 to July 1983 82 patients with
T leukaemia/lymphoma entered this study. There
were 65 boys and 17 girls (ratio 4:1) with an age
range of 13 months to 15 years. Sixteen had no
evidence of bone marrow involvement on either
aspirate or trephine biopsy, and 9 had evidence of
infiltration of the bone marrow but with <25%
blasts. These 25 patients were designated as having
had T lymphoma. Fifty-seven patients had more
than 25% T lymphoblasts in bone marrow and/or T
lymphoblasts in peripheral blood, and were
designated as having had T leukaemia; 28 of these
57 had >100 x I091 1 blasts in peripheral blood.
There were 27 NHL patients presenting with a
mediastinal mass who were treated in the parent
NHL trial (Mott et al., 1984). Careful comparison
has shown no difference between clinical features at
presentation or results of treatment in these patients
and the 25 patients treated at 6 centres for T
lymphoma in the T cell trial. Therefore for some
analyses these two groups of patients with T
lymphoma (total 52 patients) were combined.
The methodology used to establish T cell marker
status has been described previously (Greaves et al.,
1981; Habeshaw, 1980).
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Results
These are shown in Tables 1-111 and Figures 2-5.
There were no significant differences in survival and
FFS between the lymphoma patients treated on the
NHL and T cell protocols (Table I). Similar results
were obtained in the T leukaemia patients with
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Figure 2 Overall survival (...) and failure-free (-)
survival for all 82 patients in the T cell Trial.
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Figure 3 Failure-free survival for high count T
leukaemia (-) vs the rest (...).
presenting peripheral blasts <100 x O9 1, but
those with >100xlOi-' blasts did much worse
(Figure 3), the difference in survival at 4 years being
highly significant (P =0.003).
There were 66 adverse initial events (Table II)
recorded for the total of 109 patients with T cell
disease (57 patients with T leukaemia and 52
patients with T lymphoma). Forty-one of these 66
adverse events consisted of relapse in bone marrow
and/or CNS. Initial bone marrow relapse was more
frequent in those with T leukaemia (16/57 vs 6/52
for lymphoma) as was CNS relapse (9/57 vs 5/52).
Death before the achievement of complete
remission was more common in T leukaemia (6/57
vs 1/52). Patients presenting with T lymphoma had
a higher incidence of initial mediastinal relapse
(6/52 vs 1/57).
Forty-seven of the 52 patients with T lymphoma
successfully completed the induction phase of
treatment and were randomised to receive or not to
receive mediastinal radiation. There was a highly
significant difference in FFS between the two
groups in favour of the patients randomised to
receive radiation (66% vs 18%, P=0.006) Figure 4.
This difference remains significant when all patients
with T leukaemia are included (51% vs 21%,
P=0.01). The pattern of adverse events in the two
groups of lymphoma patients is shown in Table III.
Five patients were documented to have CNS
disease at their initial diagnostic lumbar puncture.
Four remain in complete remission 27, 35, 38 and
47 months from diagnosis.
Eleven patients with T leukaemia presented
without evidence of a mediastinal mass, and four
are surviving 6, 48, 56 and 56 months from
diagnosis.
Discussion
The poor prognosis for T cell disease was firmly
established when the advent of cell surface marker
Table I T cell lymphoma/leukaemia 4-year survival and failure-free survival
No. of
Diagnosis Protocol patients % Survival % FFsurvival
T lymphoma
NHL 27 48 39
T cell 25 54 40
Both 52 49 38
T leukaemia
WCC< 100 x 1091 ` T cell 29 53 37
WCC>100x 1091 1 T cell 28 20 13
All cases T cell 57 30 27460 M.G. MOTT et al.
Table II T cell lymphoma/leukaemia (109 patients).
Pattern of 1st adverse event (66)
Lymphoma (52)
Leukaemia T cell trial NHL triai
(57) (25) (27)
BM 16 4 2
BM+CNS 2 3 0
CMS 9 2 3
Local 1 1 5
Testis 3 1 2
Other 0 0 2
Death pre CR 6 1 0
Death in CR 1 2 0
Totals 38 14 14
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Figure 4 Failure-free survival for T lymphoma
patients randomised +mediastinal radiation ( x RT).
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Figure 5 Overall survival (...) and failure-free (-)
survival for 52 patients with T lymphoma.
Table III Pattern of first adverse event
in 47 patients with T lymphoma
randomised+mediastinal radiation
Radiation + -
BM 1 4
BM +CNS 1 2
CNS 0 4
Local 3 2
Testis 2 1
Other 0 1
Death in CR 1 1
Totals 8 15
- techniques made it possible to distinguish the
disorder from other lymphoid neoplasms of
childhood. The present trial had documented an
improvement in the prognosis for T lymphoma
compared to our recent previous experience
(Mathew et al., 1980) and appears to show a highly
significant advantage for those patients randomised
to receive adjuvant low dose radiation to the
mediastinum in addition to chemotherapy. Sixty-six
per cent of these patients remain in complete
remission with a plateau on the survival curve from
24 months, while patients not given mediastinal
radiation have continued to relapse throughout the
first two years after completing treatment (Figure
4).
Review of the first adverse events occurring in
these patients shows that the major differences
between the two arms of the trial are in the
frequency of spread to bone marrow and/or CNS
(2 vs 10, Table III) and in the late occurrence
of relapse in the non-radiated patients (Figure 4).
The treatment protocol called for randomisation of
patients as nearly as possible to the onset of
radiation, but this was not feasible in some centres
where radiation had to be organised at another
hospital. These required longer notice of the need
to give mediastinal radiation (randomised) in
addition to the non-randomised cranial radiation
for all patients. Review of the time to
randomisation however shows no apparent
difference between the two groups.
There were 3 patients in the group randomised to
no mediastinal radiation whose relatively early
randomisation before they had completed induction
and whose subsequent early adverse events might
have prejudiced this arm of treatment. One patient
developed clinical symptoms of CNS relapse which
was confirmed on CSF cytology before cranial
radiation had been administered; the second died in
complete remission from sepsis and pancytopaenia
associated with intermediate-dose methotrexate
administration in sub-optimal circumstances. The
01) 0z L.
0
11
0LOW DOSE RADIATION IN CHILDHOOD LEUKAEMIA/LYMPHOMA 461
third took 20 weeks to complete the induction and
consolidation phases of treatment and had
widespread disease when he presented for cranial
radiation. All might arguably have been excluded as
not evaluable on the basis of significant protocol
violations. The difference between the two groups
however remains significant (P=0.03) after their
exclusion.
Late relapses up to five years from diagnosis
were recorded in a pilot version of this protocol
(Levine et al., 1983) and for this reason publication
of the results has been delayed to a later stage than
in many otherwise comparable studies. A number
of those other studies did nevertheless appear to
show the establishment of a plateau for survival of
T lymphoma after about two years for patients
given intensive combination chemotherapy, usually
combined with radiation (Duque-Hammershaimb et
al., 1983; Anderson et al., 1983; Reihm, 1983).
In our trial where entry was confined to patients
with T cell disease, the universal previous finding of
a worse prognosis for leukaemic patients with a
high initial blast count was again confirmed. The
division between favourable and unfavourable
prognosis is, however, not set where the arbitrary
distinction is drawn between lymphoma and
leukaemia (presence of 25% blasts in bone marrow)
but is most obvious for T leukaemia patients who
present with > 100 x iO91- 1 blasts in peripheral
blood. Compared with our past experience there
has been a shift of the overall survival curve to the
right and a corresponding increase in median
survival time (24 months for all T leukaemias, 21
months for the high risk group), but late relapses
and deaths have brought the plateau of the curve to
well below 50%. The median FFS of 16 months for
T leukaemia in our study compared favourably
with the 13 month figure for a comparable group of
patients treated on the POG 7615 study (Pullen et
al., 1982).
The relative effectiveness of chemotherapy has
enabled us to show that the randomised addition of
low dose radiation to the mediastinum can increase
the survival rate of some patients, particularly those
with relatively localised disease (T lymphoma). This
effect was not detected in the companion NHL trial
where the FFS curve reached a plateau at a higher
and earlier stage, possibly because of the different
natural history of B lymphomas (Mott et al., 1984).
Review of the failures in the T cell trial suggests
that the benefit observed from radiation would not
be seen if given in conjunction with more effective
systemic chemotherapy.
The clinical features which distinguish patients
with T ALL from "Common" ALL (c ALL) are
now well established. The disease tends to occur in
older children, with a marked predilection for
males, and usually presents with a mediastinal mass,
a high peripheral blast count and also a relatively
high haemoglobin and platelet count. Patients with
T ALL have a higher rate of relapse both early and
late in the illness than do patients with c ALL.
They also have a marked predisposition to
involvement of CNS and other sites of extra-
medullary disease, such as the testes, both at
diagnosis and during the evolution of the disease.
Controversy continues about the relative
significance of particular prognostic factors such as
the initial blast count and the cell phenotype, and
the findings are likely to vary between different
treatment regimens until more effective treatment is
established.
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